One Capital Management LLC Makes New $12.53 Million Investment in Boston Scientific Corporation $BSX

One Capital Management LLC bought a new position in Boston Scientific Corporation (NYSE:BSX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 131,381 shares of the medical equipment provider’s stock, valued at approximately $12,527,000.

Other hedge funds also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter worth about $26,000. Murphy & Mullick Capital Management Corp increased its position in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. United Community Bank increased its position in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the last quarter. Colonial Trust Co SC increased its position in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares during the last quarter. Finally, Bangor Savings Bank increased its position in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 9,800 shares of company stock worth $554,012 in the last 90 days. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

BSX has been the topic of several research reports. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research report on Thursday. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Truist Financial dropped their target price on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. Finally, Robert W. Baird set a $70.00 price target on Boston Scientific in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.42.

Boston Scientific Stock Performance

BSX opened at $47.95 on Tuesday. The company has a market cap of $71.28 billion, a PE ratio of 20.06, a price-to-earnings-growth ratio of 0.89 and a beta of 0.62. The stock has a 50-day moving average of $59.79 and a 200-day moving average of $78.08. Boston Scientific Corporation has a 52-week low of $47.35 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.